HC Wainwright set a $11.00 target price on Asterias Biotherapeutics (NYSEAMERICAN:AST) in a report issued on Tuesday morning. The firm currently has a buy rating on the biotechnology company’s stock.
AST has been the subject of a number of other reports. Raymond James lowered shares of Asterias Biotherapeutics from an outperform rating to a market perform rating in a research report on Friday, August 10th. B. Riley set a $6.00 price target on shares of Asterias Biotherapeutics and gave the company a buy rating in a research report on Friday, August 3rd. Finally, Zacks Investment Research upgraded shares of Asterias Biotherapeutics from a hold rating to a buy rating and set a $1.50 price target for the company in a research report on Tuesday, July 10th.
AST opened at $1.17 on Tuesday. Asterias Biotherapeutics has a one year low of $1.07 and a one year high of $3.20.
Asterias Biotherapeutics (NYSEAMERICAN:AST) last released its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). The firm had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.11 million. Asterias Biotherapeutics had a negative net margin of 403.38% and a negative return on equity of 79.80%.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Creative Planning lifted its holdings in shares of Asterias Biotherapeutics by 50.0% during the 2nd quarter. Creative Planning now owns 180,313 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 60,100 shares during the last quarter. LMR Partners LLP bought a new stake in shares of Asterias Biotherapeutics during the 2nd quarter worth $110,000. Renaissance Technologies LLC bought a new stake in shares of Asterias Biotherapeutics during the 2nd quarter worth $142,000. Paloma Partners Management Co bought a new stake in shares of Asterias Biotherapeutics during the 2nd quarter worth $194,000. Finally, Millennium Management LLC bought a new stake in shares of Asterias Biotherapeutics during the 2nd quarter worth $663,000.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia.
Further Reading: 52-Week High/Low
Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.